Ads
related to: ezetimibe atorvastatin brand name- Dosing & Administration
Efficacy, Safety, and Dosing
Information for HCPs
- Co-Pay Program
Resources
to Support Your Patients
- Trial Results
See Clinical Data
and Trial
- Request Samples
Get patients started
with a 14-day sample
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]
Ezetimibe, sold under the brand name Zetia among others, is a medication used to treat high blood cholesterol and certain other lipid abnormalities. [3] [4] Generally it is used together with dietary changes and a statin. [5] Alone, it is less preferred than a statin. [4] It is taken by mouth. [4]
FDA Approves Merck's LIPTRUZET™ (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol LIPTRUZET Approved for Patients with Primary or Mixed Hyperlipidemia ...
Atorvastatin, sold under the brand name Lipitor among others, is a statin medication used to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels. [6] For the prevention of cardiovascular disease, statins are a first-line treatment in reducing cholesterol. [6] It is taken by mouth. [6]
Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a combination medication used to treat high cholesterol. [6] [7] In some countries it is sold as a kit or a pack containing two distinct pills. [8] [9] The combination was approved for medical use in the United States in March 2021. [4]
Brand name Derivation Metabolism [63] Half-life Atorvastatin: Arkas, Ator, Atoris, Lipitor, Torvast, Totalip: Synthetic: CYP3A4: 14–19 hours. [165] Cerivastatin: Baycol, Lipobay (withdrawn from the market in August 2001 due to risk of serious rhabdomyolysis) Synthetic: various CYP3A isoforms [166] Fluvastatin: Lescol, Lescol XL, Lipaxan ...
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
Lomitapide, sold under the brand name Juxtapid in the US and Lojuxta in the EU, is a medication used as a lipid-lowering agent for the treatment of familial hypercholesterolemia, developed by Aegerion Pharmaceuticals. [3] It has been tested in clinical trials as single treatment and in combinations with atorvastatin, ezetimibe and fenofibrate ...